Development of fluorescent contrast agents for optical imaging of mouse disease models

J. Kovar; M. Simpson; A. Schutz-Geschwender; X. Xu; W. M. Volcheck; E. Sevickmuraca; D. M. Olive

doi:10.1117/12.760815

Development of fluorescent contrast agents for optical imaging of mouse disease models

J. Kovar, M. Simpson, A. Schutz-Geschwender, X. Xu, W. M. Volcheck, E. Sevickmuraca, D. M. Olive

Biochemistry

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Abstract

Optical imaging is a rapidly developing field of research aimed at non-invasively interrogating animals for disease progression, determining the effects of a drug on a particular pathology, assessing the pharmacokinetic behavior of a drug, or identifying molecular biomarkers of disease. One of the key components of molecular imaging is the development of specific, targeted imaging contrast agents to assess mese biological processes. The development of robust fluorochrome-labeled optical agents is a process that is often underestimated in terms of its complexity. We describe here the development process and performance issues for three different optical agents: IRDye 800CW EGF (epidermal growth factor), IRDye® 800CW 2-DG (2-deoxy D-glucose), and an IRDye 680 BoneTag™. In vitro competitive assays were developed for two of the markers to demonstrate specificity. Specificity was confirmed in animal studies. Uptake of IRDye 800CW 2-DG was also examined by near-infrared confocal microscopy. Histological examinations were performed on target and non-target tissues following the completion of the imaging studies. The issues unique to the development of each labeled marker are discussed.

Original language	English (US)
Title of host publication	Molecular Probes for Biomedical Applications II
DOIs	https://doi.org/10.1117/12.760815
State	Published - 2008
Event	Molecular Probes for Biomedical Applications II - San Jose, CA, United States Duration: Jan 21 2008 → Jan 22 2008

Publication series

Name	Progress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume	6867
ISSN (Print)	1605-7422

Conference

Conference	Molecular Probes for Biomedical Applications II
Country/Territory	United States
City	San Jose, CA
Period	1/21/08 → 1/22/08

Keywords

2-deoxy-D-glucose
IRDye 680 epidermal growth factor
IRDye 800CW
Optical imaging

ASJC Scopus subject areas

Electronic, Optical and Magnetic Materials
Biomaterials
Atomic and Molecular Physics, and Optics
Radiology Nuclear Medicine and imaging

Access to Document

10.1117/12.760815

Cite this

Kovar, J., Simpson, M., Schutz-Geschwender, A., Xu, X., Volcheck, W. M., Sevickmuraca, E., & Olive, D. M. (2008). Development of fluorescent contrast agents for optical imaging of mouse disease models. In Molecular Probes for Biomedical Applications II Article 686707 (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Vol. 6867). https://doi.org/10.1117/12.760815

Development of fluorescent contrast agents for optical imaging of mouse disease models. / Kovar, J.; Simpson, M.; Schutz-Geschwender, A. et al.
Molecular Probes for Biomedical Applications II. 2008. 686707 (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Vol. 6867).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Kovar, J, Simpson, M, Schutz-Geschwender, A, Xu, X, Volcheck, WM, Sevickmuraca, E & Olive, DM 2008, Development of fluorescent contrast agents for optical imaging of mouse disease models. in Molecular Probes for Biomedical Applications II., 686707, Progress in Biomedical Optics and Imaging - Proceedings of SPIE, vol. 6867, Molecular Probes for Biomedical Applications II, San Jose, CA, United States, 1/21/08. https://doi.org/10.1117/12.760815

@inproceedings{0d8c1da8ccd848d0aac576eb05073705,

title = "Development of fluorescent contrast agents for optical imaging of mouse disease models",

abstract = "Optical imaging is a rapidly developing field of research aimed at non-invasively interrogating animals for disease progression, determining the effects of a drug on a particular pathology, assessing the pharmacokinetic behavior of a drug, or identifying molecular biomarkers of disease. One of the key components of molecular imaging is the development of specific, targeted imaging contrast agents to assess mese biological processes. The development of robust fluorochrome-labeled optical agents is a process that is often underestimated in terms of its complexity. We describe here the development process and performance issues for three different optical agents: IRDye 800CW EGF (epidermal growth factor), IRDye{\textregistered} 800CW 2-DG (2-deoxy D-glucose), and an IRDye 680 BoneTag{\texttrademark}. In vitro competitive assays were developed for two of the markers to demonstrate specificity. Specificity was confirmed in animal studies. Uptake of IRDye 800CW 2-DG was also examined by near-infrared confocal microscopy. Histological examinations were performed on target and non-target tissues following the completion of the imaging studies. The issues unique to the development of each labeled marker are discussed.",

keywords = "2-deoxy-D-glucose, IRDye 680 epidermal growth factor, IRDye 800CW, Optical imaging",

author = "J. Kovar and M. Simpson and A. Schutz-Geschwender and X. Xu and Volcheck, {W. M.} and E. Sevickmuraca and Olive, {D. M.}",

year = "2008",

doi = "10.1117/12.760815",

language = "English (US)",

isbn = "9780819470423",

series = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",

booktitle = "Molecular Probes for Biomedical Applications II",

}

TY - GEN

T1 - Development of fluorescent contrast agents for optical imaging of mouse disease models

AU - Kovar, J.

AU - Simpson, M.

AU - Schutz-Geschwender, A.

AU - Xu, X.

AU - Volcheck, W. M.

AU - Sevickmuraca, E.

AU - Olive, D. M.

PY - 2008

Y1 - 2008

N2 - Optical imaging is a rapidly developing field of research aimed at non-invasively interrogating animals for disease progression, determining the effects of a drug on a particular pathology, assessing the pharmacokinetic behavior of a drug, or identifying molecular biomarkers of disease. One of the key components of molecular imaging is the development of specific, targeted imaging contrast agents to assess mese biological processes. The development of robust fluorochrome-labeled optical agents is a process that is often underestimated in terms of its complexity. We describe here the development process and performance issues for three different optical agents: IRDye 800CW EGF (epidermal growth factor), IRDye® 800CW 2-DG (2-deoxy D-glucose), and an IRDye 680 BoneTag™. In vitro competitive assays were developed for two of the markers to demonstrate specificity. Specificity was confirmed in animal studies. Uptake of IRDye 800CW 2-DG was also examined by near-infrared confocal microscopy. Histological examinations were performed on target and non-target tissues following the completion of the imaging studies. The issues unique to the development of each labeled marker are discussed.

AB - Optical imaging is a rapidly developing field of research aimed at non-invasively interrogating animals for disease progression, determining the effects of a drug on a particular pathology, assessing the pharmacokinetic behavior of a drug, or identifying molecular biomarkers of disease. One of the key components of molecular imaging is the development of specific, targeted imaging contrast agents to assess mese biological processes. The development of robust fluorochrome-labeled optical agents is a process that is often underestimated in terms of its complexity. We describe here the development process and performance issues for three different optical agents: IRDye 800CW EGF (epidermal growth factor), IRDye® 800CW 2-DG (2-deoxy D-glucose), and an IRDye 680 BoneTag™. In vitro competitive assays were developed for two of the markers to demonstrate specificity. Specificity was confirmed in animal studies. Uptake of IRDye 800CW 2-DG was also examined by near-infrared confocal microscopy. Histological examinations were performed on target and non-target tissues following the completion of the imaging studies. The issues unique to the development of each labeled marker are discussed.

KW - 2-deoxy-D-glucose

KW - IRDye 680 epidermal growth factor

KW - IRDye 800CW

KW - Optical imaging

UR - http://www.scopus.com/inward/record.url?scp=42149110855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149110855&partnerID=8YFLogxK

U2 - 10.1117/12.760815

DO - 10.1117/12.760815

M3 - Conference contribution

AN - SCOPUS:42149110855

SN - 9780819470423

T3 - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

BT - Molecular Probes for Biomedical Applications II

T2 - Molecular Probes for Biomedical Applications II

Y2 - 21 January 2008 through 22 January 2008

ER -

Development of fluorescent contrast agents for optical imaging of mouse disease models

Abstract

Publication series

Conference

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this